Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

• Main Authors: Lene Kongsgaard Nielsen (Author), Fredrik Schjesvold (Author), Sören Möller (Author), Nina Guldbrandsen (Author), Markus Hansson (Author), Kari Remes (Author), Valdas Peceliunas (Author), Niels Abildgaard (Author), Henrik Gregersen (Author), Madeleine T. King (Author)
• Format: Book
• Published: SpringerOpen, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Decisions regarding maintenance therapy in patients with multiple myeloma should be based on both treatment efficacy and health-related quality of life (HRQL) consequences. In the CARFI trial, patients with first relapse of multiple myeloma underwent salvage autologous stem cell...